A Review on Covid-۱۹ Acute Respiratory Distress Syndrome (ARDS), and Potential Monoclonal Antibody Therapies

Publish Year: 1401
نوع سند: مقاله کنفرانسی
زبان: English
View: 157

This Paper With 13 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

BCPNU04_081

تاریخ نمایه سازی: 4 مهر 1401

Abstract:

SARS-COV-۲ or the novel coronavirus is classified as a beta-coronavirus, and causes the acute respiratory distress syndrome, which is considered to be one of the major death factors known for the SARS-COV-۲ infection. This specific type of respiratory failure is characterized by dyspnea, tachypnea, shortness of breath, and widespread inflammation in the lungs. The whole process is carried out by a rapid onset of inflammation followed by an extensive release of inflammatory mediators such as (TNFa, IL-۱, and IL-۶) causing hypoxemia, and low PaO۲/FiO۲ ratio. Along with other coronavirus infections such as SARS and MERS, which can also cause ARDS, the novel Covid-۱۹ infection poses a much higher risk to the international community than previous diseases; as a result of, very high potential for mutation. In this review, we intend to briefly mention the pathological mechanisms leading to the occurrence of ARDS, as well as promising monoclonal antibodies, which have demonstrated promising results in preventing the covid-۱۹ infection, and are believed to improve the patient’s overall condition.

Authors

Erfan hassani

Biotechnologist, Zand Institute of Higher Education, Shiraz, Iran

Ali Kiamarsi

Cellular and Molecular Biologist, Zand Institute of Higher Education, Shiraz, Iran

Mohammad Amin Nazari

Laboratory Science Student, Islamic Azad University Tehran Medical Branch, Tehran, Iran

Maryam Homayoon

Assistant Professor, Zand Institute of Higher Education, Shiraz, Iran